8-K: Organon Reports Q4, FY25 Results; Goodwill Impairment Hits Earnings

Organon & Co. announced its fourth quarter and full year 2025 financial results, reporting a net loss in Q4 due to a significant goodwill impairment and projecting flat revenue for 2026.

Summary

• Full year 2025 revenue was $6.2 billion, a 3% decrease on both an as-reported basis and at constant currency compared to 2024.
• Full year 2025 diluted earnings per share (EPS) was $0.72, significantly down from $3.33 in 2024.
• Non-GAAP Adjusted diluted EPS for full year 2025 was $3.66, an 11% decrease from $4.11 in 2024.
• Full year 2025 Adjusted EBITDA was $1.91 billion, a 3% decrease from $1.958 billion in 2024, with an Adjusted EBITDA margin of 30.7%.
• Fourth quarter 2025 total revenue was $1.507 billion, down 5% as-reported and 8% ex-FX compared to Q4 2024.
• The company reported a net loss of $205 million, or $0.79 per diluted share, for Q4 2025, primarily due to a $301 million non-cash goodwill impairment related to underperformance of several U.S. products.
• Womens Health revenue declined 1% for full year 2025 and 15% for Q4 2025, with Nexplanon sales decreasing 20% ex-FX in Q4 due to wholesaler practices, lower U.S. demand, and increased rebate rates.
• Biosimilars revenue increased 4% for full year 2025 and 11% for Q4 2025, driven by strong performance of Hadlima and contributions from new assets like Bildyos, Bilprevda, and Tofidence.
• Established Brands revenue declined 4% for full year 2025 and 2% for Q4 2025, impacted by respiratory portfolio declines and the loss of exclusivity for Atozet, partially offset by Emgality and Vtama.
• Organon's Board of Directors declared a quarterly dividend of $0.02 per share, payable on March 12, 2026, to stockholders of record on February 23, 2026.
• As of December 31, 2025, cash and cash equivalents stood at $574 million, and total debt was $8.64 billion.
• An Audit Committee review is underway regarding the timing of biosimilar purchases from a supplier in prior years, with no determination of inappropriate conduct or need for prior financial statement changes at this time.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to the significant net loss in Q4 driven by goodwill impairment, substantial decline in full-year EPS, and ongoing revenue pressures in key segments like Women's Health and Established Brands, despite some growth in Biosimilars.

Positives

• Biosimilars revenue increased 11% on both an as-reported basis and ex-FX in Q4 2025, primarily due to strong performance of Hadlima.
• The Biosimilars portfolio benefited from new assets: Bildyos and Bilprevda (approved Q3 2025) and Tofidence (acquired Q2 2025).
• The company's fertility business grew 8% ex-FX for full year 2025, driven by U.S. performance and geographic expansion.
• Adjusted EBITDA margin for full year 2025 was 30.7%, consistent with full year 2024, as the decline in Adjusted gross margin was substantially offset by lower R&D expense.
• The company expects to deliver full year 2026 revenue and Adjusted EBITDA in-line with 2025 performance, indicating stability in core metrics despite headwinds.

Negatives

• Full year 2025 revenue decreased 3% to $6.2 billion, both as-reported and at constant currency.
• Full year 2025 diluted EPS decreased significantly to $0.72 from $3.33 in 2024.
• The company reported a net loss of $205 million in Q4 2025, primarily due to a $301 million non-cash goodwill impairment related to underperformance of several U.S. products.
• Womens Health revenue declined 15% as-reported and 16% ex-FX in Q4 2025, with Nexplanon sales decreasing 20% ex-FX due to U.S. wholesaler sales practices, lower U.S. demand, and increased rebate rates.
• The fertility business in China declined due to socio-economic trends.
• Established Brands revenue declined 2% as-reported and 5% ex-FX in Q4 2025, driven by pricing pressure in the respiratory portfolio (particularly in the U.S. and China) and volume declines related to revised medical guidelines for montelukast (Singulair).
• Reported gross margin in Q4 2025 was 49.2% (down from 56.3% in Q4 2024) and for full year 2025 was 53.3% (down from 58.0% in 2024), primarily due to one-time costs for manufacturing network optimization, unfavorable pricing, foreign exchange rates, and product mix.
• Renflexis and Ontruzant biosimilars declined 8% ex-FX and 30% ex-FX, respectively, for full year 2025 due to mature product life cycles and significant competitive pricing pressure.

Risks

• The timing and completion of the Audit Committee's review regarding biosimilar purchases and the potential results thereof.
• Global pricing pressures, including governmental regulations, managed care rules, and international reference pricing.
• Changes in government laws and regulations affecting product development, approval, manufacturing, and marketing, as well as environmental and tax laws.
• Economic factors such as inflation, interest rates, recessionary pressures, and foreign currency exchange rates.
• The company's inability to remediate material weaknesses in its internal control over financial reporting.
• The impact of substantial levels of indebtedness on the company's financial flexibility and operations.
• Expanded brand and class competition in the markets where the company operates.
• Difficulties with the performance of third parties, including suppliers and commercial counterparties, leading to increased costs or failure to meet obligations.
• Competition from generic products as the company's products lose patent protection, including the potential loss of market exclusivity for Nexplanon after 2027.
• The continued impact of the September 2024 loss of exclusivity for Atozet.
• Cyberattacks, failures, accidents, or security breaches of the company's or third-party IT systems.
• Increased focus on privacy issues and evolving legislative and regulatory landscapes for data protection.
• Efficacy, safety, or other quality concerns with marketed products, potentially leading to recalls, withdrawals, or declining sales.
• Delays or failures in demonstrating adequate efficacy and safety of product candidates in clinical trials, hindering development and commercialization.
• Legal factors, including product liability claims, antitrust litigation, governmental investigations, tax disputes, and patent disputes.

Future Outlook

Organon expects to deliver approximately $6.2 billion in revenue and $1.9 billion in Adjusted EBITDA for the full year 2026, both measures in-line with 2025 performance. The company anticipates that the annual revenue foregone from the JADA system divestiture will be approximately offset by favorable currency translation, resulting in constant currency revenue growth about flat with the prior year, pro forma for the divestiture. Adjusted gross margin is projected to be 75-100 basis points lower than 2025, while SG&A and R&D expenses are expected to remain in the mid-20% and mid-single-digit ranges, respectively.

Management Comments

• "In 2025 we took action that demonstrated our commitment to improving the balance sheet and to building more financial flexibility." Joe Morrissey, interim Chief Executive Officer.
• "In 2026 our primary objective is to maintain operational performance that aligns with last year. At the same time, we remain committed to disciplined expense management and capital deployment to achieve progress on our deleveraging efforts." Joe Morrissey, interim Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Organon's performance reflects broader challenges in the pharmaceutical industry, particularly for established brands facing patent expirations and pricing pressures, as seen with Atozet and the respiratory portfolio. The growth in biosimilars, driven by Hadlima and new product launches, aligns with a growing industry trend towards biosimilar adoption as a cost-effective alternative. The decline in U.S. Nexplanon sales due to policy-related access restrictions highlights the significant impact of healthcare policy on specific product categories, a common risk for pharmaceutical companies. The goodwill impairment indicates a re-evaluation of asset values in a competitive and evolving market, a trend observed across companies with diverse portfolios.

Comparison to Industry Standards

• The 3% decline in full-year revenue for Organon contrasts with some larger pharmaceutical companies that have managed to achieve modest growth or maintain revenue stability through new product launches or strategic acquisitions. For example, companies like Pfizer or Merck, while facing their own patent cliffs, often leverage a broader pipeline or M&A to offset declines more effectively.
• The significant drop in diluted EPS from $3.33 to $0.72, largely due to a $301 million goodwill impairment, indicates a substantial re-assessment of asset values. This level of impairment can be more pronounced than what is typically seen in stable, mature pharmaceutical companies, suggesting specific challenges within Organon's acquired or established product lines.
• The 11% growth in Biosimilars revenue in Q4 2025, driven by Hadlima and new launches like Bildyos and Bilprevda, is a positive sign and aligns with the strong growth trajectory seen in the global biosimilar market. This segment's performance is comparable to the growth rates reported by dedicated biosimilar players or divisions within larger pharmaceutical firms, demonstrating Organon's competitive positioning in this specific area.
• The decline in Nexplanon sales due to 'policy-related access restrictions' in the U.S. highlights a vulnerability to regulatory and reimbursement changes, a common challenge in the highly regulated healthcare sector. This specific impact could be more severe than general market fluctuations, potentially indicating a less diversified revenue stream or higher reliance on specific policy frameworks compared to peers with broader product portfolios or geographic reach.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Will experience a significant decrease in diluted EPS and a net loss in Q4 2025 due to goodwill impairment. The declared quarterly dividend of $0.02 provides some return, but the overall financial performance and flat outlook for 2026 may temper investor confidence. The Audit Committee review introduces uncertainty.
• **Employees:** The company's commitment to 'disciplined expense management' and 'optimizing the company's manufacturing and supply network' could imply potential restructuring or efficiency initiatives that might affect employment.
• **Customers:** Policy-related access restrictions and increased rebate rates for products like Nexplanon could impact patient access and affordability in certain markets. The divestiture of the JADA system means customers for that product will now deal with a different entity.
• **Suppliers:** The Audit Committee review concerning the timing of biosimilar purchases from a supplier in prior years could lead to scrutiny or changes in supplier relationships, particularly for the supplier under review.
• **Creditors:** The company's substantial debt of $8.64 billion and a net leverage ratio of ~4.3x, alongside a commitment to deleveraging, indicates that debt management remains a priority. The flat revenue and EBITDA outlook for 2026 suggests no significant improvement in debt-servicing capacity in the short term, but also no further deterioration.

Next Steps

• The Audit Committee will conduct a review regarding the timing of biosimilar purchases from a supplier in prior years.
• The company anticipates timely filing of its Form 10-K for the year ended December 31, 2025, and updating its disclosure in relation to the Audit Committee matter.
• Organon will host a conference call on February 12, 2026, to discuss its fourth quarter and full year financial results.
• The company aims to maintain operational performance in 2026 that aligns with 2025, focusing on disciplined expense management and capital deployment for deleveraging efforts.

Key Dates

Recommendation

The filing presents a mixed picture with significant negatives, including a substantial goodwill impairment leading to a net loss in Q4 and a sharp decline in full-year EPS. Revenue growth is stagnant, and key segments face headwinds from pricing pressure and policy changes. However, the Biosimilars segment shows strong growth, and management is committed to disciplined expense management and deleveraging. The 2026 guidance projects flat performance, suggesting stability but no immediate catalysts for significant upside. The ongoing Audit Committee review adds a layer of uncertainty. Given the challenges and lack of strong growth catalysts, but also the stability in core Adjusted EBITDA and the dividend, a 'hold' recommendation is appropriate for investors awaiting clearer signs of turnaround or sustained growth.

Keywords

Pharmaceuticals, Healthcare, Womens Health, Biosimilars, Established Brands, Financial Results, Earnings, SEC Filing, Organon, OGN, Goodwill Impairment, Nexplanon, Hadlima, Atozet, Dividend